---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-008508"
form_type: "8-K"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2024-03-01T23:59:59+00:00"
generated_at: "2026-06-05T05:46:56.103517+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# ZyVersa Therapeutics receives approval to transfer stock listing from Nasdaq Global Market to Capital Market

## Summary
- Received Nasdaq approval on Feb 29, 2024 to transfer listing from Global Market to Capital Market.
- Transfer effective as of open of business on March 1, 2024; ticker ZVSA unchanged.
- Cures prior deficiency in minimum Market Value of Publicly Held Shares (MVPHS) requirement.
- Company had 7,583,863 shares of common stock outstanding as of March 1, 2024.
- Nasdaq Capital Market has similar corporate governance requirements but different listing standards.

## SEC filing metadata
- accession: 0001493152-24-008508
- form_type: 8-K
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2024-03-01T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000149315224008508/0001493152-24-008508-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000149315224008508/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-008508
- JSON: https://secwatch.observer/filing/0001493152-24-008508.json
- Plain text: https://secwatch.observer/filing/0001493152-24-008508.txt

## Key facts
- Listing & Compliance Notices
  ZyVersa Therapeutics, Inc. received a nasdaq compliance regained notice regarding market value (rules 5450(b)(1)(C)).
  - Exchange: nasdaq
  - Notice: compliance regained
  - Deficiency: market value
  - Rules: 5450(b)(1)(C)
  source text: February 29, 2024, the Company received approval from Nasdaq to transfer the listing of the Company’s Common Stock from the Nasdaq Global Market to the Nasdaq Capital Market (the “Approval”). The Company’s Common Stock will be transferred to the Nasdaq Capital Market effective as of the open of business on March 1, 2024, and will continue to trade under the symbol “ZVSA.” The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, and listed companies must meet certain financial requirements and comply with Nasdaq’s corporate governance requirements. As of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1859007/000149315224008508/0001493152-24-008508-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.